Clinical Trial Update: Study Evaluating the Efficacy and Safety of Cyclosporine Reduction in Kidney Transplant Recipients Receiving Sirolimus [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial update examines the efficacy and safety of reducing cyclosporine exposure in kidney transplant recipients treated with sirolimus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• CYCLOSPORINE (cyclosporine)
• Sirolimus (Sirolimus)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Kidney Transplantation | Phase 4 | Status: COMPLETED